Dr. Kevin Kim on T-VEC in Melanoma

Kevin B. Kim, MD
Published: Thursday, May 14, 2015



Kevin B. Kim, MD, medical oncology, California Pacific Medical Center, discusses T-VEC as a treatment option for melanoma.

Kim says T-VEC is an interesting approach to treating the disease. It has shown promising outcomes in studies, he adds, including a phase III trial in which it demonstrated a significant improvement in overall survival, close to the P value.

T-VEC's concept of breaking up the tumor and releasing the tumor antigen is effective, Kim explains, because it will "wake up" the immune system.

Though he questions T-VEC's efficacy as a single agent, Kim is interested in seeing if it will show higher efficacy when combined with ipilimumab or a PD-1 antibody.



Kevin B. Kim, MD, medical oncology, California Pacific Medical Center, discusses T-VEC as a treatment option for melanoma.

Kim says T-VEC is an interesting approach to treating the disease. It has shown promising outcomes in studies, he adds, including a phase III trial in which it demonstrated a significant improvement in overall survival, close to the P value.

T-VEC's concept of breaking up the tumor and releasing the tumor antigen is effective, Kim explains, because it will "wake up" the immune system.

Though he questions T-VEC's efficacy as a single agent, Kim is interested in seeing if it will show higher efficacy when combined with ipilimumab or a PD-1 antibody.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Evolving Roles for Targeted Melanoma Therapies: Assessing Rapid Progress in the Field and Looking Toward Future CombinationsFeb 28, 20191.5
Advances in™ Melanoma: Exploring BRAF/MEK in Adjuvant and Neoadjuvant SettingsSep 28, 20191.5
Publication Bottom Border
Border Publication
x